Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Why Is Nektar Therapeutics Stock Trading Higher On Thursday? (CORRECTED)

Nektar_Sign-San_Francisco-1

Editor’s Note: This article has been updated to correct an earlier inaccuracy regarding the company’s stock trajectory.

Nektar Therapeutics Inc. (NASDAQ:NKTR) on Thursday shared new data from its ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, at the 2025 European Academy of Dermatology and Venereology Congress.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.